[go: up one dir, main page]

FR25C1007I1 - Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie - Google Patents

Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie

Info

Publication number
FR25C1007I1
FR25C1007I1 FR25C1007C FR25C1007C FR25C1007I1 FR 25C1007 I1 FR25C1007 I1 FR 25C1007I1 FR 25C1007 C FR25C1007 C FR 25C1007C FR 25C1007 C FR25C1007 C FR 25C1007C FR 25C1007 I1 FR25C1007 I1 FR 25C1007I1
Authority
FR
France
Prior art keywords
methods
treating disease
epinephrine formulations
intranasal epinephrine
intranasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1007C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ars Pharmaceuticals Operations Inc
Aegis Therapeutics LLC
Original Assignee
Ars Pharmaceuticals Operations Inc
Aegis Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68593261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR25C1007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US15/890,131 external-priority patent/US10576156B2/en
Priority claimed from PCT/US2019/016918 external-priority patent/WO2019157099A1/fr
Application filed by Ars Pharmaceuticals Operations Inc, Aegis Therapeutics LLC filed Critical Ars Pharmaceuticals Operations Inc
Publication of FR25C1007I1 publication Critical patent/FR25C1007I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR25C1007C 2018-02-06 2025-02-17 Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie Active FR25C1007I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/890,131 US10576156B2 (en) 2004-08-25 2018-02-06 Compositions for drug administration
US201862685049P 2018-06-14 2018-06-14
US201862734550P 2018-09-21 2018-09-21
US201862784057P 2018-12-21 2018-12-21
PCT/US2019/016918 WO2019157099A1 (fr) 2018-02-06 2019-02-06 Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie

Publications (1)

Publication Number Publication Date
FR25C1007I1 true FR25C1007I1 (fr) 2025-04-04

Family

ID=68593261

Family Applications (1)

Application Number Title Priority Date Filing Date
FR25C1007C Active FR25C1007I1 (fr) 2018-02-06 2025-02-17 Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie

Country Status (25)

Country Link
EP (3) EP4169511A1 (fr)
KR (4) KR20240165490A (fr)
CN (2) CN116549389A (fr)
AU (3) AU2019217643B2 (fr)
BR (1) BR112020015646A2 (fr)
CA (1) CA3088989C (fr)
CY (1) CY1125856T1 (fr)
DE (1) DE112019000683T5 (fr)
ES (2) ES2791775B2 (fr)
FI (2) FI3678649T3 (fr)
FR (1) FR25C1007I1 (fr)
GB (3) GB2583051B (fr)
HR (1) HRP20221525T1 (fr)
HU (2) HUE060917T2 (fr)
IL (1) IL276485B2 (fr)
LT (2) LT3678649T (fr)
MA (1) MA50106A (fr)
MX (2) MX2020008132A (fr)
NO (1) NO2025010I1 (fr)
PL (1) PL3678649T3 (fr)
PT (1) PT3678649T (fr)
RS (1) RS63866B1 (fr)
SG (1) SG11202007527XA (fr)
SI (1) SI3678649T1 (fr)
SM (1) SMT202300099T1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
WO2024082281A1 (fr) * 2022-10-21 2024-04-25 Nanjing Haiwei Pharmaceutical Technologies Co., Ltd. Nouvelles formulations d'épinéphrine et leurs utilisations
CN118121542A (zh) * 2023-03-31 2024-06-04 中国药科大学 鼻用药物组合物、其制备方法及应用
CN118121543A (zh) * 2023-03-31 2024-06-04 中国药科大学 鼻用药物组合物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US9895444B2 (en) * 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2011139838A2 (fr) * 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Formulations intranasales
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
TW201440811A (zh) * 2013-02-12 2014-11-01 Ys Pharmtech 腎上腺素製劑藥品
EP3082817A4 (fr) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions pour administration de médicaments
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations

Also Published As

Publication number Publication date
MX2023002506A (es) 2023-03-13
AU2021254650A1 (en) 2021-11-18
EP4483958A3 (fr) 2025-03-05
CA3088989C (fr) 2023-03-07
KR20240019858A (ko) 2024-02-14
ES2935684T3 (es) 2023-03-09
ES2791775A2 (es) 2020-11-05
GB2583051B (en) 2020-12-02
KR20220035512A (ko) 2022-03-22
HUS2500010I1 (hu) 2025-03-28
SI3678649T1 (sl) 2023-04-28
GB2600026B (en) 2022-10-12
LTPA2025507I1 (fr) 2025-02-25
DE112019000683T5 (de) 2020-10-15
MX2020008132A (es) 2020-11-18
CN110505873A (zh) 2019-11-26
AU2021254650B2 (en) 2024-02-22
IL276485B1 (en) 2024-08-01
GB2587934B (en) 2022-01-19
GB202117505D0 (en) 2022-01-19
AU2024201523A1 (en) 2024-03-28
GB2587934A (en) 2021-04-14
EP4483958A2 (fr) 2025-01-01
EP4169511A1 (fr) 2023-04-26
KR102733397B1 (ko) 2024-11-21
GB2583051A (en) 2020-10-14
KR102375232B1 (ko) 2022-03-16
CN110505873B (zh) 2022-12-30
KR20240165490A (ko) 2024-11-22
SG11202007527XA (en) 2020-09-29
IL276485A (en) 2020-09-30
FI3678649T3 (fi) 2023-01-31
HRP20221525T1 (hr) 2023-03-03
CY1125856T1 (el) 2024-09-20
IL276485B2 (en) 2024-12-01
CA3088989A1 (fr) 2019-08-15
KR20200121818A (ko) 2020-10-26
CN116549389A (zh) 2023-08-08
EP3678649A4 (fr) 2020-10-14
LT3678649T (lt) 2023-02-10
FIC20250011I1 (fi) 2025-02-21
AU2019217643B2 (en) 2021-10-28
PT3678649T (pt) 2023-01-16
BR112020015646A2 (pt) 2020-12-08
RS63866B1 (sr) 2023-01-31
NO2025010I1 (no) 2025-02-14
PL3678649T3 (pl) 2023-05-08
EP3678649B1 (fr) 2022-10-26
ES2791775B2 (es) 2023-01-20
MA50106A (fr) 2021-04-21
SMT202300099T1 (it) 2023-05-12
EP3678649A1 (fr) 2020-07-15
GB202016960D0 (en) 2020-12-09
AU2019217643A1 (en) 2020-08-13
GB202012086D0 (en) 2020-09-16
HUE060917T2 (hu) 2023-04-28
EP3678649B8 (fr) 2022-11-16
GB2600026A (en) 2022-04-20
ES2791775R1 (es) 2021-07-02

Similar Documents

Publication Publication Date Title
FR25C1007I1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3891175A4 (fr) Protéines modifiées et méthodes de traitement associées
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3668500A4 (fr) Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
MA54132A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
MA54313A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP3716949A4 (fr) Méthodes de traitement d'une maladie auto-immune
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
MA48743A (fr) Composés et méthodes de traitement d'infections bactériennes
MA51787A (fr) Substances et méthodes de traitement d'hémoglobinopathies